Merck & Co., Inc. (NYSE: MRK) is having an incredibly strong start to the trading session this morning, and for good reason. The company released positive results from a key Phase 3 clinical trial, leading to excitement among investors and sending the stock toward the top. Today, we’ll talk about the results, what we’re seeing from MRK, and what we’ll be watching for ahead.
MRK Announces Positive Clinical Results
As mentioned above, Merck & Co. is having an incredibly strong start to the trading session this morning after releasing positive results from a key Phase 3 clinical trial. In a press release issued early this morning, the company announced that the pivotal Phase 3 KEYNOTE-189 clinical trial met its dual primary endpoint.
In the clinical trial, MRK investigated the efficacy of KEYTRUDA® in combination with pemetrexed (ALIMTA®) and cisplatin or carboplatin, for first line treatment in patients with metastatic or non-squamous non-small cell lung cancer.
According to the release, the study met its dual primary endpoints. In the release, MRK said that the treatment led to increased overall survival as well as progression free survival. MRK informed investors that full results from the clinical trial will be presented at an upcoming medical meeting as well as submitted to regulatory authorities. In a statement, Dr. Roger M. Perlmutter, President at Merck Research Laboratories had the following to say about the results: